This paper presents the results of an open-label, individually randomized controlled trial of a single dose of a modern intravenous iron formulation, ferric carboxymaltose, for anaemia treatment in pregnant women in Malawi with a singleton pregnancy of 13–26 weeks' gestation in primary care and outpatient settings.